學術文獻-基石藥業

臨床模式蘇州轉化醫學研究中心產品管線學術文獻

Home - 研究開發 - 學術文獻

學術文獻

臨床模式 
蘇州轉化醫學研究中心 
產品管線 
學術文獻 

GEMSTONE-302: Randomized, Double-Blind, Phase 3 Study of Sugemalimab or Placebo Plus Platinum-Based Chemotherapy as First-Line Treatment for Metastatic NSCLC

發表在：2021年世界肺癌大會 (WCLC)
Abstract 53 GEMSTONE-302: A Phase 3 Study of Platinum-Based Chemotherapy with Placebo or Sugemalimab, a PD-L1mAb, for metastatic NSCLC

發表在：2021年世界肺癌大會（WCLC)
Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer

發表在：2021年世界肺癌大會（WCLC)
Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer

發表在：2021年世界肺癌大會（WCLC)
CS5001, a novel ROR1 targeting antibody drug conjugate (ADC) armed with tumor cleavable β glucuronide linkers and pyrrolobenzodiazepine (PBD) prodrugs for hematological and solid malignancies

發表在：2021年第33屆國際分子靶標與癌癥治療大會
Abstract LBA008: CS5001, a novel ROR1-targeting antibody drug conjugate (ADC) armed with tumor-cleavable β-glucuronide linkers and pyrrolobenzodiazepine (PBD) prodrugs for hematological and solid malignancies

發表在：2021年第33屆國際分子靶標與癌癥治療大會
Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors

發表在：發表在：2021年歐洲腫瘤內科學會（ESMO）年會
Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors

發表在：2021年歐洲免疫腫瘤學大會(ESMO IO)

1 2 3 4 5 6 7

上一頁4/12下一頁

聲明